Drug Trial Radar · NCT00000665
Studies of the Ocular Complications of AIDS (SOCA) CMV Retinitis Trial: Foscarnet-Ganciclovir Component
Last checked: Nov 19, 2026Latest source record: Mar 14, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
240
Actual
Start
Not stated
Primary completion
Apr 1992
Sponsor
- Sponsor type
- NIH
- Collaborators
- Johns Hopkins University
- First posted
- Aug 31, 2001
Design
- Study type
- Interventional
- Phase
- Not applicable
- Primary purpose
- Treatment
- Who can join
- All sexes, from 13 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the relative effectiveness and safety of foscarnet versus ganciclovir for the treatment of cytomegalovirus (CMV) retinitis in people with AIDS; to evaluate the relative effect on survival of the use of these two anti-CMV agents in the treatment of CMV retinitis; to compare the relative benefits of immediate treatment with foscarnet or ganciclovir versus deferral of treatment for CMV retinitis limited to less than 25 percent of zones 2 and 3. CMV retinitis is a common opportunistic infection in patients with AIDS. Ganciclovir is currently the only drug approved for treatment of CMV retinitis in immunocompromised patients. Ganciclovir suppresses CMV infections, and relapse occurs in virtually all AIDS patients when ganciclovir is discontinued. Because of their similar hematologic (blood) toxicities, the simultaneous use of ganciclovir and zidovudine (AZT) is not recommended. More recently the drug foscarnet has become available for investigational use. Studies so far indicate that remission of CMV retinitis occurs in 36 to 77 percent of patients, and that relapse occurs in virtually all patients when the drug is discontinued. The relative effectiveness of foscarnet compared with ganciclovir for the immediate control of CMV infections is unknown. Further, the long-term effects of foscarnet or ganciclovir on CMV retinitis, survival, and morbidity are unknown. There is also no definitive information on the relative effectiveness and safety of deferred versus immediate treatment for CMV retinitis confined to zones 2 and 3.
Conditions
- Cytomegalovirus Retinitis
- HIV Infections
Interventions
Foscarnet sodiumDrug
GanciclovirDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
UCSD - Shiley Eye Ctr / SOCA
La Jolla, California
UCLA - Jules Stein Eye Institute / SOCA
Los Angeles, California
UCSF - San Francisco Gen Hosp
San Francisco, California
Northwestern Univ / SOCA
Chicago, Illinois
Charity Hosp / Tulane Univ Med School
New Orleans, Louisiana
Johns Hopkins Hosp / SOCA
Baltimore, Maryland
New York Univ Med Ctr / SOCA
New York, New York
New York Hosp - Cornell Med Ctr / Sloan - Kettering / SOCA
New York, New York
Mount Sinai Med Ctr / SOCA
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.